Zevra Therapeutics Inc (ZVRA)
6.92
-0.39
(-5.34%)
USD |
NASDAQ |
Sep 27, 16:00
6.92
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Research and Development Expense (Annual): 39.81M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 39.81M |
| December 31, 2022 | 19.80M |
| December 31, 2021 | 10.16M |
| December 31, 2020 | 8.843M |
| December 31, 2019 | 19.42M |
| December 31, 2018 | 41.76M |
| Date | Value |
|---|---|
| December 31, 2017 | 20.59M |
| December 31, 2016 | 20.47M |
| December 31, 2015 | 13.93M |
| December 31, 2014 | 11.92M |
| December 31, 2013 | 3.367M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.843M
Minimum
2020
39.81M
Maximum
2023
19.61M
Average
19.42M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Vanda Pharmaceuticals Inc | 76.82M |
| BioCardia Inc | 7.726M |
| Verrica Pharmaceuticals Inc | 20.30M |
| Xeris Biopharma Holdings Inc | 22.34M |
| Crinetics Pharmaceuticals Inc | 168.53M |